welcome to STERNA BIOLOGICALS
Treatment of type 2 inflammatory diseases by GATA-3 downregulation
LATEST PRESS RELEASES
sterna biologicals announces dosing of first patient in phase IIA proof-of-concept study with SB010 in moderate to severe asthma
Marburg, Germany, December 14, 2021 GIANT-1 study to evaluate once-daily oral inhalation of novel catalytic antisense oligonucleotide formulation SB010 in patients with moderate to severe Type-2 driven asthma Standard of care remains insufficient for large number of these asthmatics Study incorporates digital therapy to enhance patient device handling, increase adherence, reduce drop-out rates ...
READ MOREsterna biologicals receives approval for innovative phase II a study design in asthma combining a novel antisense-based treatment with a digital therapy
Marburg, Germany, November 23, 2021 Phase IIa proof-of-concept (POC) study with novel catalytic antisense oligonucleotide SB010 in patients with moderate to severe asthma initiated. Innovative study design combines pharmacological therapy with VisionHealth’s Kata® Clinical, a unique combination of artificial intelligence, and computer animation to enhance patients’ device handling, adherence, ...
READ MOREsterna biologicals raises further EUR 10.0 million (approx. USD 11.9 million) in series A - 2nd closing private placement
Marburg, Germany, January 07, 2021 Following successful completion of the company’s Series A – 1st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million Proceeds from the 2nd closing will fund phase IIb preparatory activities including toxicology studies and CMC work for ...
READ MOREsterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement
Marburg, Germany, May 26, 2020 Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes Topical ...
READ MORE
sterna biologicals
sterna biologicals is an innovative clinical-stage immunology company developing novel immunomodulation therapies for patients suffering from type 2 inflammatory diseases.
The GATA-3 Approach
GATA-3 is a key master transcription factor in type 2 inflammation. GATA-3 downregulation could provide a novel, first-in-class anti-inflammatory treatment approach.
Pipeline
sterna biologicals has a clinically validated development pipeline with lead candidates in asthma and ulcerative colitis.
BIO-Europe
Spring 2021
March 22–25, 2021
Delivered Digitally
